Olmesartan medoxomil is a prodrug that is rapidly hydrolyzed into olmesartan in the gastrointestinal tract. Olmesartan is rapidly absorbed from the gastrointestinal tract into the body, with a maximum plasma concentration of 0.22-2.1 mg/L and time to Cmax of 1.4-2.8 h following administration of olmesartan medoxomil 10-160 mg (Schwocho and Masonson 2001). For the same doses, the mean area under the concentration-time curve (AUC) was 1.6-19.9 mgh/L.
Olmesartan medoxomil(CAS NO:144689-63-4) should be used with caution in renal artery stenosis. Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients.
It should also be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an Olmesartan medoxomil.
There are some side effects of Olmesartan medoxomil we should take care of.
Dizziness or lightheadedness may occur as your body adjusts to the medication. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if any of these unlikely but serious side effects occur: fainting, slow/irregular heartbeat, unusual decrease in the amount of urine.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Olmesartan medoxomil has been evaluated for safety in more than 3825 patients/subjects, including more than 3275 patients treated for hypertension in controlled trials. This experience included about 900 patients treated for at least 6 months and more than 525 for at least 1 year. Treatment with Olmesartan medoxomil was well tolerated, with an incidence of adverse reactions similar to placebo. Events generally were mild, transient and had no relationship to the dose of Olmesartan medoxomil.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. Want to learn more information about Olmesartan medoxomil, you can access the guidechem.com.
没有评论:
发表评论